Ophthalmology

The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

More research is needed to fully understand the associations with different types of strabismus

Patients with diabetes mellitus have the highest odds of being diagnosed with an undetected eye disease.

An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.

Allen Ho, MD, discusses the Protocol W outcomes and what they indicate for prescribing ophthalmologists.

The PACIFIC study is currently evaluating health care management practice with intravitreal ranibizumab 0.5 mg for various ophthalmologic diseases.

An ARVO 2021 study characterizes patients with diabetic retinopathy who have also developed diabetic macular edema.

The innovative technology is associated with significantly improved time to tear breakup, meibum quality, and improved inflammatory markers.

Based on personal clinical experience, Arshad Khanani, MD, explains his current approach to treating wet age-related macular degeneration with anti-VEGF therapy, with special considerations for appropriate dosage and timing of injections, and describes how he assesses patient response to therapy.

Dr Arshad Khanani describes the role of anti-VEGF therapy for wet age-related macular degeneration and elaborates on factors that impact treatment selection and sequencing in a patient’s continuum of care.

Strategies that can be used to screen and confirm a diagnosis of age-related macular degeneration, as well as monitor patients to optimize care.

Arshad Khanani, MD, defines age-related macular degeneration as it relates to vision loss, highlighting the ways the condition may present in patients and its impact on quality of life.

Anti-VEGF administration did increase the risk of nonocular hemorrhages, mostly in patients with AMD.

The cumulative incidence of disease among participants in the low-, medium-, and high-risk tertiles was 31.7%, 47.6%, and 59.8%, respectively.

SDOCT imaging shows that sickle cell patients with no clinical evidence of retinopathy have considerably lower central macular thickness when compared with healthy controls.

Some exposed newborns with negative PCR assays presented with fundus abnormalities.

Contrast suppression was substantially lower for patients with major depressive disorder.

The investigators found lower absolute T-MoCA scores in the NTG arm of the study when compared to the high tension glaucoma cohort.

Some fear repeated injections of anti-VEGF drugs might harm retinal nerve fiber layer, but a new study finds little evidence of such harm.

Patients with subjective vision changes should be referred for fundus examination.

Patients who underwent the therapy also had greater myopic shift compared to those that did not.

The launch of a My Retina Tracker dramatically increased testing rates, which could help lead to better clinical trials and therapies.

Investigators noted a higher prevalence of nuclear sclerotic cataracts in infected patients versus uninfected patients.